Discontinued — last reported Q4 '22
Edwards Lifesciences Income from Discontinued Ops decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 100.0%, from -$7.20M to $0.00. Over 3 years (FY 2022 to FY 2025), Income from Discontinued Ops shows a downward trend with a -59.2% CAGR.
Generally neutral, but large losses may indicate poor past strategic decisions or restructuring costs.
This represents the net gain or loss from business segments or product lines that the company has sold, shut down, or in...
Only present for companies undergoing significant portfolio restructuring or M&A activity.
discontinued_operations| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $49.48M | $49.48M | $49.48M | $49.48M | $39.90M | $51.30M | $48.80M | $36.60M | $26.10M | $1.00M | $2.71B | $39.30M | -$7.20M | -$4.40M | -$2.00M | $27.00M | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -19.4% | +28.6% | -4.9% | -25.0% | -28.7% | -96.2% | >999% | -98.5% | -118.3% | +38.9% | +54.5% | >999% | -100.0% |
| YoY Change | — | — | — | — | -19.4% | +3.7% | -1.4% | -26.0% | -34.6% | -98.1% | >999% | +7.4% | -127.6% | -540.0% | -100.1% | -31.3% | +100.0% |